Philippe Ruszniewski Selected Research

lanreotide (Somatuline)

1/2019	Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
5/2017	Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
5/2016	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
10/2014	Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
7/2014	Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
2/2013	Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
1/2004	Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
1/2004	Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Ruszniewski Research Topics

Disease

64	Neoplasms (Cancer) 11/2021 - 05/2002
31	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2022 - 01/2009
22	Neoplasm Metastasis (Metastasis) 11/2022 - 09/2002
18	Adenocarcinoma 05/2018 - 08/2002
12	Pancreatitis 10/2019 - 04/2003
11	Pancreatic Neoplasms (Pancreatic Cancer) 10/2019 - 05/2002
10	Neoplasms, Cystic, Mucinous, and Serous 05/2018 - 11/2008
9	Chronic Pancreatitis 10/2019 - 02/2002
8	Carcinoid Tumor (Carcinoid) 01/2021 - 02/2002
6	Diarrhea 03/2021 - 08/2004
6	Disease Progression 01/2021 - 01/2004
6	Hypoxia (Hypoxemia) 01/2018 - 10/2008
5	Neuroendocrine Carcinoma 01/2021 - 04/2011
5	Primitive Neuroectodermal Tumors (PNET) 06/2018 - 01/2014
4	Carcinoma (Carcinomatosis) 02/2021 - 02/2008
4	Autoimmune Pancreatitis 10/2019 - 12/2007
3	Fatigue 01/2021 - 02/2011
3	Cholangitis 10/2019 - 06/2005
3	Exocrine Pancreatic Insufficiency 10/2019 - 01/2011
3	Pain (Aches) 01/2018 - 01/2004
3	Insulinoma 05/2013 - 02/2002
3	Multiple Endocrine Neoplasia Type 1 04/2012 - 01/2009
3	Adenoma (Adenomas) 01/2010 - 08/2002
2	Abdominal Pain (Pain, Abdominal) 03/2021 - 11/2005
2	Flushing 03/2021 - 02/2002
2	Acute Necrotizing Pancreatitis 01/2021 - 01/2004
2	Necrosis 01/2021 - 04/2014
2	Nausea 01/2021 - 02/2011
2	Fibrosis (Cirrhosis) 11/2018 - 07/2010
2	Hypertrophy 11/2018 - 04/2008
2	Pancreatic Diseases (Pancreatic Disease) 06/2017 - 11/2009
2	Inborn Genetic Diseases (Disease, Hereditary) 11/2016 - 01/2012
2	Cysts 01/2016 - 10/2002
2	Pancreatic Fistula (Pancreatic Fistulas) 05/2015 - 07/2010
2	Cystic Fibrosis (Mucoviscidosis) 05/2015 - 09/2007
2	Serous Cystadenoma 05/2015 - 06/2004
2	Hemorrhage 05/2015 - 01/2006
2	Mucinous Cystadenoma 04/2014 - 06/2004
2	Carcinogenesis 04/2014 - 03/2013
2	Ulcer 11/2013 - 01/2006
2	Hypertension (High Blood Pressure) 06/2012 - 07/2010
2	Alcoholic Pancreatitis 02/2012 - 06/2003
2	Lymphatic Metastasis 01/2010 - 10/2008
2	Zollinger-Ellison Syndrome (Syndrome, Zollinger-Ellison) 12/2007 - 11/2005
2	Ischemia 08/2005 - 01/2004

Drug/Important Bio-Agent (IBA)

14	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2021 - 01/2004
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
10	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2004
8	lanreotide (Somatuline)FDA Link 01/2019 - 01/2004
8	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2018 - 09/2006
7	Biological ProductsIBA 12/2019 - 11/2006
6	Kazal Pancreatic Trypsin InhibitorIBA 10/2019 - 02/2002
5	Chromogranin AIBA 05/2017 - 11/2005
4	Temozolomide (Temodar)FDA LinkGeneric 10/2020 - 01/2009
4	Sunitinib (Sutent)FDA Link 01/2018 - 12/2009
4	Tumor Biomarkers (Tumor Markers)IBA 01/2016 - 10/2002
4	Everolimus FDA Link 01/2016 - 01/2010
3	Serotonin (5 Hydroxytryptamine)IBA 11/2022 - 05/2017
3	lutetium Lu 177 dotatateIBA 03/2021 - 12/2017
3	Streptozocin (Streptozotocin)FDA Link 10/2020 - 01/2004
3	Capecitabine (Xeloda)FDA Link 01/2020 - 12/2014
3	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 01/2004
3	GastrinsIBA 05/2017 - 11/2005
3	Hormones (Hormone)IBA 05/2017 - 01/2010
3	Glucagon (Glukagon)FDA Link 05/2015 - 05/2006
3	Insulin (Novolin)FDA Link 05/2015 - 05/2006
3	GadoliniumIBA 01/2014 - 03/2012
3	TrypsinogenIBA 01/2012 - 02/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2010 - 05/2009
3	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 08/2010 - 02/2002
3	DEET (DET)IBA 01/2009 - 04/2008
2	Alkylating AgentsIBA 11/2021 - 10/2020
2	Octreotide (Sandostatin)FDA LinkGeneric 03/2021 - 12/2017
2	PlatinumIBA 02/2021 - 09/2012
2	Monoclonal AntibodiesIBA 01/2021 - 01/2018
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2021 - 06/2015
2	Dacarbazine (DIC)FDA LinkGeneric 10/2020 - 01/2019
2	SteroidsIBA 10/2019 - 01/2011
2	Azathioprine (Imuran)FDA LinkGeneric 10/2019 - 01/2011
2	Carbonic Anhydrase IXIBA 01/2018 - 05/2009
2	Peptides (Polypeptides)IBA 05/2015 - 01/2008
2	N 30IBA 03/2015 - 04/2003
2	TrypsinIBA 01/2013 - 12/2006
2	Gemcitabine FDA Link 09/2012 - 08/2011
2	erucylphosphocholineIBA 03/2012 - 11/2008
2	Immunoglobulin G (IgG)IBA 01/2012 - 01/2011
2	Complementary DNA (cDNA)IBA 11/2006 - 05/2002

Therapy/Procedure

23	Therapeutics 03/2021 - 01/2004
19	Drug Therapy (Chemotherapy) 11/2021 - 01/2004
14	Pancreatectomy 01/2021 - 11/2003
11	Pancreaticoduodenectomy 05/2015 - 01/2004
4	Ligation 04/2008 - 07/2003
3	Hepatectomy 01/2021 - 09/2002
3	Liver Transplantation 06/2017 - 09/2002
2	Neoadjuvant Therapy 12/2019 - 03/2013
2	Laparotomy 05/2014 - 06/2013
2	Length of Stay 05/2014 - 06/2013
2	Operative Time 06/2013 - 07/2010
2	Critical Care (Surgical Intensive Care) 02/2013 - 07/2008
2	Antibiotic Prophylaxis 02/2012 - 01/2006